BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28341972)

  • 1. A prospective study of aromatase inhibitor therapy initiation and self-reported side effects.
    Gallicchio L; Calhoun C; Helzlsouer K
    Support Care Cancer; 2017 Sep; 25(9):2697-2705. PubMed ID: 28341972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy.
    Gallicchio L; MacDonald R; Wood B; Rushovich E; Helzlsouer KJ
    Climacteric; 2012 Aug; 15(4):339-49. PubMed ID: 22191462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aromatase inhibitor therapy and hair loss among breast cancer survivors.
    Gallicchio L; Calhoun C; Helzlsouer KJ
    Breast Cancer Res Treat; 2013 Nov; 142(2):435-43. PubMed ID: 24197658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.
    Kidwell KM; Harte SE; Hayes DF; Storniolo AM; Carpenter J; Flockhart DA; Stearns V; Clauw DJ; Williams DA; Henry NL
    Cancer; 2014 Aug; 120(16):2403-11. PubMed ID: 24802413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial.
    Graetz I; McKillop CN; Stepanski E; Vidal GA; Anderson JN; Schwartzberg LS
    J Cancer Surviv; 2018 Aug; 12(4):431-440. PubMed ID: 29492753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein and musculoskeletal symptoms.
    Helzlsouer KJ; Gallicchio L; MacDonald R; Wood B; Rushovich E
    Breast Cancer Res Treat; 2012 Jan; 131(1):277-85. PubMed ID: 21904883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
    Gallicchio L; Macdonald R; Wood B; Rushovich E; Helzlsouer KJ
    Breast Cancer Res Treat; 2011 Nov; 130(2):569-77. PubMed ID: 21647676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.
    Crew KD; Greenlee H; Capodice J; Raptis G; Brafman L; Fuentes D; Sierra A; Hershman DL
    J Clin Oncol; 2007 Sep; 25(25):3877-83. PubMed ID: 17761973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy.
    Li H; Sereika SM; Marsland AL; Conley YP; Bender CM
    J Clin Nurs; 2019 Dec; 28(23-24):4560-4571. PubMed ID: 31469461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in bone biomarker concentrations and musculoskeletal symptoms among breast cancer patients initiating aromatase inhibitor therapy and women without a history of cancer.
    Gallicchio L; MacDonald R; Wood B; Rushovich E; Fedarko NS; Helzlsouer KJ
    J Bone Miner Res; 2012 Sep; 27(9):1959-66. PubMed ID: 22508239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer.
    Gallicchio L; MacDonald R; Helzlsouer KJ
    J Cancer Res Clin Oncol; 2013 May; 139(5):837-43. PubMed ID: 23408333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
    Egawa C; Hirokaga K; Takao S; Yamagami K; Miyashita M; Baba M; Ichii S; Konishi M; Kikawa Y; Minohata J; Okuno T; Miyauchi K; Wakita K; Suwa H; Hashimoto T; Nishino M; Matsumoto T; Hidaka T; Konishi Y; Sakoda Y; Miya A; Mitsunobu M; Nishikawa H; Kono S; Kokufu I; Sakita I; Kitatsuji K; Oh K; Miyoshi Y
    Int J Clin Oncol; 2016 Apr; 21(2):262-269. PubMed ID: 26411314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.
    Brier MJ; Chambless DL; Gross R; Chen J; Mao JJ
    Cancer; 2017 Jan; 123(1):169-176. PubMed ID: 27570979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient and physician perceptions on continuing aromatase inhibitors beyond the 5-year mark.
    Gandhi S; Towns K; Verma S
    Breast J; 2011; 17(6):620-9. PubMed ID: 21943336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Cepa M; Vaz C
    Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study.
    Pedersini R; Monteverdi S; Mazziotti G; Amoroso V; Roca E; Maffezzoni F; Vassalli L; Rodella F; Formenti AM; Frara S; Maroldi R; Berruti A; Simoncini E; Giustina A
    Bone; 2017 Apr; 97():147-152. PubMed ID: 28104509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
    Mincey BA; Duh MS; Thomas SK; Moyneur E; Marynchencko M; Boyce SP; Mallett D; Perez EA
    Clin Breast Cancer; 2006 Jun; 7(2):127-32. PubMed ID: 16800971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
    MarĂ­a RS; Marta PM; Sonia S; Natalia GG; Tamara M; Ignasi T; Maria MG; Jaime RM; Adolfo DP; Joan A; Xavier N
    Bone; 2016 Nov; 92():1-8. PubMed ID: 27519968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer.
    Philipovskiy A; Campbell A; Heydarian R; Castillo B; Dwivedi AK; McCallum R; Aguilera R; Gaur S; Nahleh Z
    Anticancer Res; 2020 Feb; 40(2):857-864. PubMed ID: 32014929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.